EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4

Eine Phase-2a-Studie des IL-33-Antikörpers Tozorakimab bei Patient:innen mit COPD: FRONTIER-4

Dave Singh, Patricia Guller, Fred Reid, Sarah Doffman, Ulla Seppälä, Ioannis Psallidas, Rachel Moate, Rebecca Smith, Joanna Kiraga, Eulalia Jimenez, Dennis Brooks, Aoife Kelly und 6 weitere

European Respiratory Journal · 2025-07 · 66 (1) · 2402231

DOI: 10.1183/13993003.02231-2024 ↗

Auf einen Blick

In einer randomisierten Phase-2a-Studie zeigte Tozorakimab bei COPD keine signifikante Verbesserung des primären Endpunkts, aber positive Wirksamkeitssignale in einer Subgruppe mit häufigen Exazerbationen.

Fragestellung

Wirkt Tozorakimab bei Patient:innen mit moderat bis schwerer COPD und chronischer Bronchitis unter dualer oder triple inhalativer Therapie besser als Placebo?

Methode

Randomisierte, doppelblinde, placebokontrollierte Phase-2a-Studie; Tozorakimab 600 mg oder Placebo s.c. alle 4 Wochen für 24 Wochen; primärer Endpunkt: FEV1 präbronchodilatatorisch bis Woche 12.

Ergebnisse

135 Patient:innen (Tozorakimab 67; Placebo 68). Woche 12: präbronchodilatatorisches FEV1 LSMD 24 mL (80 %-KI −15–63; p=0,216), postbronchodilatatorisch 67 mL (80 %-KI 17–116; p=0,044).

Schlussfolgerung der Autor:innen

Obwohl der primäre Endpunkt in der ITT-Population nicht erreicht wurde, zeigte Tozorakimab positive Wirksamkeitssignale versus Placebo in einer Subgruppe mit hohem Exazerbationsrisiko.

Kernaussagen

  • Primärer Endpunkt in der ITT-Population nicht signifikant erreicht
  • Postbronchodilatatorisches FEV1 verbessert: LSMD 67 mL
  • Kein signifikanter Rückgang der COPD-Exazerbationen in der ITT-Population

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Respiratory Journal, online erschienen am 28.03.2025. Verfasst von Dave Singh und 17 weiteren Autor:innen. Beteiligte Einrichtung: Medicines Evaluation Unit, Manchester University NHS Foundation Trust, University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Antibodies, Monoclonal, Humanized, Interleukin-33, Antibodies, Monoclonal. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interleukin-33 may have a role in COPD pathobiology. FRONTIER-4 ( NCT04631016 ) investigated tozorakimab (an anti-interleukin-33 monoclonal antibody) in patients with moderate-to-severe COPD with chronic bronchitis receiving dual or triple inhaled therapy.

Methods

FRONTIER-4 was a phase 2a, randomised, double-blind, placebo-controlled study. Patients received tozorakimab 600 mg or placebo subcutaneously every 4 weeks for 24 weeks. The primary end‑point was change in pre-bronchodilator forced expiratory volume in 1 s (FEV 1 ) from baseline to week 12. Secondary outcomes included post-bronchodilator FEV 1 , time-to-first COPD composite exacerbation event and safety.

Results

The intent-to-treat population included 135 patients (tozorakimab, n=67; placebo, n=68). At week 12 in the intent-to-treat population, tozorakimab showed a greater increase, although nonsignificant, from baseline in pre-bronchodilator FEV 1 (least-squares mean difference (LSMD) 24 mL, 80% confidence interval (CI) −15–63 mL, p=0.216) and a significantly greater increase in post-bronchodilator FEV 1 (LSMD 67 mL, 80% CI 17–116 mL, p=0.044) when compared with placebo. At week 12 in a prespecified subgroup of patients with at least two prior exacerbations, tozorakimab also showed improvements versus placebo in change from baseline in pre-bronchodilator FEV 1 (LSMD 69 mL, 80% CI 9–130 mL, p=0.072) and post-bronchodilator FEV 1 (LSMD 124 mL, 80% CI 47–201 mL, p=0.020). Tozorakimab did not significantly reduce the risk of COPD composite exacerbation events (hazard ratio 0.79, 80% CI 0.57–1.11, p=0.186) in the intent-to-treat population, although there were greater effects in patients with at least two prior exacerbations (hazard ratio 0.61, 80% CI 0.37–1.00). Results were similar in former and current smokers. Tozorakimab was well tolerated.

Conclusion

Although the primary end-point was not met in the intent-to-treat population, tozorakimab showed positive efficacy signals versus placebo in a subgroup of patients with COPD with a high risk of exacerbations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveAntibodies, Monoclonal, HumanizedInterleukin-33Antibodies, MonoclonalHumansMaleFemaleDouble-Blind MethodAgedMiddle AgedForced Expiratory VolumeTreatment OutcomeBronchodilator AgentsAdministration, Inhalation

Substanzen

Antibodies, Monoclonal, HumanizedInterleukin-33Bronchodilator AgentsIL33 protein, humanAntibodies, Monoclonal

Autor:innen und Institutionen

  • Medicines Evaluation Unit, Manchester University NHS Foundation Trust, University of Manchester, Manchester, UK.
  • Clinical Development, Research and Early Development, Respiratory and Immunology, AstraZeneca, Gothenburg, Sweden.
  • Clinical Development, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA.
  • Biometrics and Statistical Innovation, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Early Phase Clinical Operations, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland.

ORCID-Profile: Maria G Belvisi

Förderung

  • AstraZeneca

Zitieren

APA

Singh, D., Guller, P., Reid, F., Doffman, S., Seppälä, U., Psallidas, I., Moate, R., Smith, R., Kiraga, J., Jimenez, E., Brooks, D., Kelly, A., Nordenmark, L. H., Sadiq, M. W., Caballero, L. M., Kell, C., Belvisi, M. G., & Pandya, H. (2025). A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4. European Respiratory Journal, 66(1), 2402231. https://doi.org/10.1183/13993003.02231-2024

Vancouver

Singh D, Guller P, Reid F, Doffman S, Seppälä U, Psallidas I, et al. A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4. European Respiratory Journal. 2025;66(1):2402231. doi:10.1183/13993003.02231-2024

BibTeX
@article{Singh2025,
  author = {Singh, Dave and Guller, Patricia and Reid, Fred and Doffman, Sarah and Seppälä, Ulla and Psallidas, Ioannis and Moate, Rachel and Smith, Rebecca and Kiraga, Joanna and Jimenez, Eulalia and Brooks, Dennis and Kelly, Aoife and Nordenmark, Lars H and Sadiq, Muhammad Waqas and Caballero, Luis Mateos and Kell, Chris and Belvisi, Maria G and Pandya, Hitesh},
  title = {A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4},
  journal = {European Respiratory Journal},
  year = {2025},
  volume = {66},
  number = {1},
  pages = {2402231},
  doi = {10.1183/13993003.02231-2024}
}
Kostenlos starten →